Bourgeon Capital Management LLC Has $14.55 Million Position in Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Bourgeon Capital Management LLC cut its position in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 0.5% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 659,955 shares of the company’s stock after selling 3,366 shares during the period. Teva Pharmaceutical Industries makes up about 2.7% of Bourgeon Capital Management LLC’s holdings, making the stock its 8th largest holding. Bourgeon Capital Management LLC’s holdings in Teva Pharmaceutical Industries were worth $14,545,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in the company. FMR LLC boosted its holdings in Teva Pharmaceutical Industries by 49.5% in the 3rd quarter. FMR LLC now owns 62,740,763 shares of the company’s stock valued at $1,130,589,000 after purchasing an additional 20,762,226 shares during the period. Clal Insurance Enterprises Holdings Ltd boosted its stake in Teva Pharmaceutical Industries by 6.8% during the third quarter. Clal Insurance Enterprises Holdings Ltd now owns 34,543,812 shares of the company’s stock valued at $621,337,000 after buying an additional 2,204,623 shares during the period. State Street Corp grew its position in Teva Pharmaceutical Industries by 10.0% during the third quarter. State Street Corp now owns 19,500,683 shares of the company’s stock worth $351,402,000 after buying an additional 1,778,268 shares in the last quarter. Geode Capital Management LLC increased its stake in Teva Pharmaceutical Industries by 3.4% in the 3rd quarter. Geode Capital Management LLC now owns 8,792,011 shares of the company’s stock worth $157,571,000 after acquiring an additional 291,124 shares during the last quarter. Finally, Janus Henderson Group PLC raised its holdings in shares of Teva Pharmaceutical Industries by 7,945.2% in the 3rd quarter. Janus Henderson Group PLC now owns 4,791,937 shares of the company’s stock valued at $86,350,000 after acquiring an additional 4,732,374 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on TEVA shares. Barclays raised their price target on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the company an “overweight” rating in a research report on Wednesday, December 18th. StockNews.com cut Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 18th. Piper Sandler upped their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research note on Monday, October 21st. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.13.

Insider Buying and Selling

In other news, EVP Christine Fox sold 19,388 shares of the stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total value of $327,075.56. Following the sale, the executive vice president now directly owns 44,104 shares in the company, valued at approximately $744,034.48. This represents a 30.54 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of the business’s stock in a transaction on Friday, December 20th. The shares were sold at an average price of $22.01, for a total value of $6,294,860.00. Following the transaction, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. The trade was a 29.15 % decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by insiders.

Teva Pharmaceutical Industries Price Performance

Shares of NYSE TEVA opened at $21.86 on Wednesday. Teva Pharmaceutical Industries Limited has a twelve month low of $11.08 and a twelve month high of $22.80. The company has a debt-to-equity ratio of 2.57, a quick ratio of 0.61 and a current ratio of 0.89. The company has a 50 day moving average of $19.33 and a 200 day moving average of $18.26.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.